Equities

PureTech Health PLC

PRTC:LSE

PureTech Health PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)202.50
  • Today's Change-6.50 / -3.11%
  • Shares traded103.32k
  • 1 Year change-10.79%
  • Beta1.1859
Data delayed at least 20 minutes, as of Jun 24 2024 12:31 BST.
More ▼

Profile data is unavailable for this security.

About the company

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

  • Revenue in GBP (TTM)2.63m
  • Net income in GBP-51.96m
  • Incorporated2015
  • Employees90.00
  • Location
    PureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
  • Phone+1 (617) 482-2333Fax+1 (617) 482-3337
  • Websitehttps://puretechhealth.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Animalcare Group Plc74.35m1.20m142.48m226.00142.48m226.00
Avacta Group Plc23.25m-24.95m170.55m154.00170.55m154.00
hVIVO PLC56.04m16.12m185.74m274.00185.74m274.00
4Basebio PLC506.00k-7.67m198.48m--198.48m--
Alliance Pharma plc180.68m-33.14m226.43m292.00226.43m292.00
Bioventix PLC13.60m8.67m227.06m16.00227.06m16.00
Allergy Therapeutics plc53.26m-50.22m250.24m635.00250.24m635.00
Niox Group PLC36.80m9.50m292.59m85.00292.59m85.00
Oxford BioMedica plc89.54m-157.49m328.44m714.00328.44m714.00
Puretech Health PLC2.63m-51.96m566.45m90.00566.45m90.00
Genus plc673.10m33.40m1.12bn3.48k1.12bn3.48k
Indivior PLC888.89m3.95m1.77bn1.05k1.77bn1.05k
Data as of Jun 24 2024. Currency figures normalised to PureTech Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

61.89%Per cent of shares held by top holders
HolderShares% Held
Invesco Asset Management Ltd.as of 06 Jun 202450.21m18.57%
Lansdowne Partners (UK) LLPas of 31 Mar 202324.37m9.01%
Baillie Gifford & Co.as of 31 Mar 202322.52m8.33%
Jupiter Asset Management Ltd.as of 15 Jul 202014.25m5.27%
M&G Investment Management Ltd.as of 31 Mar 202311.76m4.35%
Miller Value Partners LLCas of 31 Mar 202110.04m3.71%
Patient Capital Management, Inc.as of 31 Mar 20239.81m3.63%
Eurizon Capital SGR SpAas of 03 Jun 20249.56m3.54%
Patient Capital Management LLC (Invt Mgmt)as of 28 Mar 20249.50m3.51%
Canaccord Genuity Asset Management Ltd.as of 07 Oct 20225.34m1.98%
More ▼
Data from 31 Mar 2024 - 03 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.